In vivo targeting of antibody fragments to the nervous system for Alzheimer’s disease immunotherapy and molecular imaging of amyloid plaques
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Targeting therapeutic or diagnostic proteins to the nervous system is limited by the presence of the blood–brain barrier. We report that a F(ab′)2 fragment of a monoclonal antibody against fibrillar human Aβ42 that is polyamine (p)‐modified has increased permeability at the blood–brain barrier, comparable binding to the antigen, and comparable in vitro binding to amyloid plaques in Alzheimer’s disease (AD) transgenic mouse brain sections. Intravenous injection of the pF(ab′)2 4.1 in the AD transgenic mouse demonstrated efficient targeting to amyloid plaques throughout the brain, whereas the unmodified fragment did not. Removal of the Fc portion of this antibody derivative will minimize the inflammatory response and cerebral hemorrhaging associated with passive immunization and provide increased therapeutic potential for treating AD. Coupling contrast agents/radioisotopes might facilitate the molecular imaging of amyloid plaques with magnetic resonance imaging/positron emission tomography. The efficient delivery of immunoglobulin G fragments may also have important applications to other neurodegenerative disorders or for the generalized targeting of nervous system antigens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397
Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · cited 2×
“…et al. 2000; Weiner et al. 2000; Lemere et al. 2003), and passive immunization with monoclonal or polyclonal antibodies by intravenous, peritoneal, intracerebral, or ventricular injections (Bard et al. 2000; DeMattos et al. 2001; Dodart et al. 2002; Mohajeri et al. 2002; Wilcock et al. 2003).”
BackgroundImmunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
Dodart, J.-C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., et al. (2002) · Nature Neuroscience · doi:10.1038/nn842 · Cited by 858
Cerebral Hemorrhage After Passive Anti-Aβ Immunotherapy
Pfeifer, M., Boncristiano, S., Bondolfi, L., Stalder, A., Deller, T., Staufenbiel, M., Mathews, P. M., & Jucker, M. (2002) · Science · doi:10.1126/science.1078259 · Cited by 511
Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning
Schenk, D. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn938 · Cited by 436
Macromolecular permeability across the blood-nerve and blood-brain barriers.
Poduslo, J. F., Curran, G. L., & Berg, C. T. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5705 · Cited by 377
Self-citationVaccination with soluble Aβ oligomers generates toxicity‐neutralizing antibodies
Lambert, M. P., Viola, K. L., Chromy, B. A., Chang, L., Morgan, T. E., Yu, J., Venton, D. L., Krafft, G. A., Finch, C. E., & Klein, W. L. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00592.x · Cited by 349
Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy
Bacskai, B. J., Kajdasz, S. T., McLellan, M. E., Games, D., Seubert, P., Schenk, D., & Hyman, B. T. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-18-07873.2002 · Cited by 323
Wilcock, D. M., DiCarlo, G., Henderson, D., Jackson, J., Clarke, K., Ugen, K. E., Gordon, M. N., & Morgan, D. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-09-03745.2003 · Cited by 232 · cited 1×
“…et al. 2000; Weiner et al. 2000; Lemere et al. 2003), and passive immunization with monoclonal or polyclonal antibodies by intravenous, peritoneal, intracerebral, or ventricular injections (Bard et al. 2000; DeMattos et al. 2001; Dodart et al. 2002; Mohajeri et al. 2002; Wilcock et al. 2003).”
BackgroundWilcock, D. M., Munireddy, S. K., Rosenthal, A., Ugen, K. E., Gordon, M. N., & Morgan, D. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.09.015 · Cited by 202
In Vivo Magnetic Resonance Microimaging of Individual Amyloid Plaques in Alzheimer's Transgenic Mice
Jack, C. R., Wengenack, T. M., Reyes, D. A., Garwood, M., Curran, G. L., Borowski, B. J., Lin, J., Preboske, G. M., Holasek, S. S., Adriany, G., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2588-05.2005 · Cited by 148
Self-citationMonsonego, A., Imitola, J., Zota, V., Oida, T., & Weiner, H. L. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.5.2216 · Cited by 91 · cited 2×
“Active immunization may trigger autoinflammatory reactions and cell lysis due to T-cell activation (Grubeck-Loebenstein et al. 2000; Monsonego et al. 2003) or induce autoimmune reactions due to antibody binding to neuronal epitopes (Rohn et al.”
Background
Cited by
CNS Delivery Via Adsorptive Transcytosis
Hervé, F., Ghinea, N., & Scherrmann, J.-M. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9055-2 · Cited by 676
Bates, K. A., Verdile, G., Li, Q.-X., Ames, D., Hudson, P., Masters, C. L., & Martins, R. N. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.96 · Cited by 247
David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments
Bates, A., & Power, C. A. (2019) · Antibodies · doi:10.3390/antib8020028 · Cited by 237
Wang, A., Das, P., Switzer, R. C., Golde, T. E., & Jankowsky, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5077-10.2011 · Cited by 118
“Several groups are testing ways to increase the brain penetrance of peripherally delivered antibody, including polyamine modification or ultrasonic disruption of the blood– brain barrier (Poduslo et al., 2007; Choi et al., 2008; Raymond et al., 2008).”
BackgroundEngineering Theranostic Nanovehicles Capable of Targeting Cerebrovascular Amyloid Deposits
Agyare, E. K., Jaruszewski, K. M., Curran, G. L., Rosenberg, J. T., Grant, S. C., Lowe, V. J., Ramakrishnan, S., Paravastu, A. K., Poduslo, J. F., & Kandimalla, K. K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.010 · Cited by 71
Self-citation
Metadata
- Authors
- Poduslo, J. F., Ramakrishnan, M., Holasek, S. S., Ramirez‐Alvarado, M., Kandimalla, K. K., Gilles, E. J., Curran, G. L., & Wengenack, T. M.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2007-03-21
- Volume
- 102
- Issue
- 2
- Pages
- 420-433
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1559704329
- Cited by
- 89
- References
- 17
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.